Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development

Krause, B; Öhlinger, R.

doi:10.1016/j.ejogrb.2005.11.013

Cited by 15 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…progesterone, luteal phase supplementation with hCG resulted in better conception rates, 4 while other studies reported that hCG administration as a form of luteal supplementation did not have significant benefits in comparison with progesterone supplementation. 5,6 The administration of hCG leads to an increased production of estradiol and progesterone by the corpus luteum. 7 In addition to its classical endocrine role, a series of studies has shown that hCG exerts paracrine effects in the uterine environment.…”

Section: Introductionmentioning

confidence: 99%

Is human chorionic gonadotropin supplementation beneficial for frozen and thawed embryo transfer in estrogen/progesterone replacement cycles?: A randomized clinical trial

Shiotani

Matsumoto

Okamoto

et al. 2017

Reprod Medicine & Biology

View full text Add to dashboard Cite

AimHuman chorionic gonadotropin (hCG) is used frequently for luteal support in fresh in vitro fertilization cycles as it induces progesterone secretion from the ovaries after oocyte retrieval and modulates the endometrium for implantation in fresh cycles. In contrast, hCG is not usually used for the transfer of cryopreserved‐thawed embryos in estrogen/progesterone replacement cycles because ovulation is suppressed. However, several studies have shown that luteinizing hormone and hCG receptors are present in the human endometrium and that hCG can directly induce the decidualization of endometrial stromal cells in vitro. Thus, this study evaluated whether hCG supplementation can be beneficial for cryopreserved‐thawed embryo transfer in estrogen/progesterone replacement cycles.MethodsOne‐hundred‐and seventy‐three cryopreserved‐thawed embryo transfer cycles with estrogen/progesterone replacement were divided randomly into two groups. Transdermal oestradiol was used in combination with vaginal progesterone suppositories for HR. The embryo transfer was performed on day 17 and/or day 20 of the HR therapy cycle in both groups. In Group A, 3000 IU of hCG was administered on days 17, 20, and 23. In Group B, hCG was not used.ResultsThere was no significant difference in the average age of the patients, the average number of previous assisted reproductive technology cycles, or the average number of embryo transfers between the two groups. The rates of pregnancy and implantation per embryo were 37.2% and 25.3%, respectively, in Group A and 35.6% and 21.7%, respectively, in Group B. The pregnancy and implantation rates were similar in both groups.ConclusionSupplementation with hCG is not beneficial for cryopreserved‐thawed embryo transfer in estrogen/progesterone replacement cycles.

show abstract

Section: Introductionmentioning

confidence: 99%

Is human chorionic gonadotropin supplementation beneficial for frozen and thawed embryo transfer in estrogen/progesterone replacement cycles?: A randomized clinical trial

Shiotani

Matsumoto

Okamoto

et al. 2017

Reprod Medicine & Biology

View full text Add to dashboard Cite

show abstract

“…Intramuscular urinary hCG (2,000 international units/3 days, three times) and dydrogesterone 10 mg twice daily were given after ovulation for luteal phase support. 17,18…”

Section: Methodsmentioning

confidence: 99%

“…Intramuscular urinary hCG (2,000 international units/3 days, three times) and dydrogesterone 10 mg twice daily were given after ovulation for luteal phase support. 17,18 For patients assigned to the artificial cycle FET group, oral valerate estradiol (2 mg Progynova, twice daily) was prescribed on the fifth day of progesterone-induced bleeding. Seven days later, an ultrasound examination was performed to measure endometrial thickness, as well as to ensure that no dominant follicle emerged.…”

Section: Methodsmentioning

confidence: 99%

Letrozole During Frozen Embryo Transfer in Women With Polycystic Ovarian Syndrome

Yuan,

Chang,

Wen

et al. 2023

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

OBJECTIVE: To compare live-birth rates between letrozole application and artificial cycle for endometrium preparation during frozen embryo transfer (FET) cycle among women with polycystic ovarian syndrome (PCOS). METHODS: A randomized controlled trial was conducted. Women with PCOS were randomized to letrozole application for ovulation induction compared with artificial cycle for endometrial preparation during FET. The primary outcome was live-birth rate per embryo transfer. Secondary outcomes included pregnancy-related outcomes, perinatal outcomes, and maternal complication rates. Assuming α=0.05 and 80% power, 186 patients per group were required to demonstrate a difference of 15% in live-birth rate: 205 patients (at least) per group were randomized to allow for a 10% dropout rate. RESULTS: Four hundred twenty patients were enrolled from 2018 to 2021. Two hundred ten patients were assigned to the letrozole application group, and 210 were assigned to the artificial cycle group. There was no difference in the live-birth rate (42.4% vs 42.9%, P=>.99). There was no difference in secondary outcomes, including clinical pregnancy rate (51.4% vs 56.2%, P=.378), implantation rate (51.8% vs 55.8%, P=.401), and miscarriage rate (8.6% vs 11.0%, P=.511). For perinatal outcomes, singleton birth weight was significantly higher in the artificial cycle group (3,108±56 g vs 3,301±58, P=.018), and the incidence of gestational diabetes mellitus (GDM) was significantly higher in letrozole application group (14.6% vs 5.6%, P=.050). The other outcome was no difference in maternal complications. CONCLUSION: There was no difference in pregnancy outcomes between letrozole application compared with artificial cycle for endometrial preparation in women with PCOS who underwent FET. The risk of GDM was higher in the letrozole application group, and the singleton birth weight was lower in the artificial cycle group. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1800014746.

show abstract

“…Progesterone, estradiol, human chorionic gonadotropin (hCG), or gonadotropin releasing hormone agonists (GnRHa) have been evaluated in a variety of clinical studies as a means of luteal phase support to increase implantation and pregnancy rates in IVF ( 2 , 3 , 4 , 5 ) . More recent studies have suggested that intrauterine injections of hCG just before embryo transfer (ET) can increase pregnancy rates ( 2 , 6 , 7 ) .…”

Section: Introductionmentioning

confidence: 99%

Outcome of intracytoplasmic sperm injection after preinstillation of a gonadotropin releasing hormone agonist in the uterine cavity just before embryo transfer

Aytaç

Haydardedeoğlu

Özdemir

et al. 2017

tjod

View full text Add to dashboard Cite

Objective:To evaluate the effects of a gonadotropin releasing hormone agonist (GnRHa) injection prior to embryo transfer on implantation and pregnancy rate.Materials and Methods:We performed a retrospective analysis of patients undergoing in vitro fertilization (IVF) therapy with and without GnRHa preinstallation into the uterine cavity just before embryo transfer between January 2012 and March 2013 in a single IVF center of a university hospital. Patients were evaluated based upon implantation, pregnancy, live birth, and miscarriage rates.Results:GnRHa was injected into the uterine cavity of 108 patients prior to embryo transfer which were regarded as study group. One thousand forty-seven patients who were not injected GnRHa were regarded as the control group. Pregnancy rates were 44.4% and 41.7% in the GnRHa and control groups, respectively. Live birth rates were 27.8% and 26.1%, miscarriage rates were 15.7% and 15.7%, and implantation rates were 31% and 30%, respectively and there were no difference between groups statistically (p>0.05).Conclusion:No statistically significant differences in implantation, pregnancy, live birth, or miscarriage rates were observed in patients treated with GnRHa prior to embryo transfer, relative to the controls. Therefore, GnRHa injection into the uterine cavity prior to embryo transfer is not recommended as a means of increasing implantation or pregnancy rates in IVF. However, prospective randomized controlled studies are needed to clarify the effect of GnRHa instillation in the uterine cavity for embryo implantation in IVF.

show abstract

Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development

Cited by 15 publications

References 32 publications

Is human chorionic gonadotropin supplementation beneficial for frozen and thawed embryo transfer in estrogen/progesterone replacement cycles?: A randomized clinical trial

Is human chorionic gonadotropin supplementation beneficial for frozen and thawed embryo transfer in estrogen/progesterone replacement cycles?: A randomized clinical trial

Letrozole During Frozen Embryo Transfer in Women With Polycystic Ovarian Syndrome

Outcome of intracytoplasmic sperm injection after preinstillation of a gonadotropin releasing hormone agonist in the uterine cavity just before embryo transfer

Contact Info

Product

Resources

About